Exvastat news post image

CounterCOVID study reaches 50% recruitment milestone

Exvastat is pleased to announce the CounterCOVID trial of oral imatinib in Severe COVID-19 infection has reached the milestone of 50% recruitment into the 386-patient study.

The full details of the study protocol can be found here:

Exvastat receives prestigious Innovative Medicines Initiative grant to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS

Read more
1 2